A randomized, controlled, phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus ADT alone in metastatic hormone-sensitive prostate cancer (ARANOTE).

被引：3

作者：

Haresh, K. P.

Vjaters, Egils

Castellano, Daniel

Olmos, David

Shore, Neal D.

Nevalaita, Liina

Testa, Isabella

Kappeler, Christian

Kuss, Iris

Saad, Fred

机构：

[1] All India Inst Med Sci, New Delhi, India

[2] P Stradins Clin Univ Hosp, Riga, Latvia

[3] Univ Hosp 12 Octubre, Madrid, Spain

[4] Ctr Nacl Invest Oncol, Madrid, Spain

[5] Carolina Urol Res Ctr, Myrtle Beach, SC USA

[6] Orion Corp, Orion Pharma, Espoo, Finland

[7] Bayer SpA, Milan, Italy

[8] Bayer AG, Berlin, Germany

[9] Univ Montreal, Ctr Hosp, Montreal, PQ, Canada

来源：

关键词：

D O I：

10.1200/JCO.2022.40.6_suppl.TPS200

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS200

引用

页数：3